Christopher D. Thanos

1.7k total citations
25 papers, 1.3k citations indexed

About

Christopher D. Thanos is a scholar working on Molecular Biology, Biotechnology and Oncology. According to data from OpenAlex, Christopher D. Thanos has authored 25 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 8 papers in Biotechnology and 6 papers in Oncology. Recurrent topics in Christopher D. Thanos's work include Cancer Research and Treatments (7 papers), Virus-based gene therapy research (5 papers) and Monoclonal and Polyclonal Antibodies Research (5 papers). Christopher D. Thanos is often cited by papers focused on Cancer Research and Treatments (7 papers), Virus-based gene therapy research (5 papers) and Monoclonal and Polyclonal Antibodies Research (5 papers). Christopher D. Thanos collaborates with scholars based in United States, Italy and Canada. Christopher D. Thanos's co-authors include James U. Bowie, Kenneth E. Goodwill, James A. Wells, H. Michael Shepard, Marc Feldmann, Gail D. Lewis Phillips, Warren L. DeLano, Mike Randal, Dwaine F. Emerich and Trevor J. Hallam and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and Journal of the American Chemical Society.

In The Last Decade

Christopher D. Thanos

23 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Christopher D. Thanos United States 13 835 446 382 151 138 25 1.3k
Dorothea Reilly United States 20 1.2k 1.5× 415 0.9× 588 1.5× 292 1.9× 73 0.5× 28 1.7k
Anna Maria Gasparri Italy 24 1.1k 1.3× 692 1.6× 265 0.7× 456 3.0× 191 1.4× 44 2.0k
M. Inoue Japan 11 922 1.1× 568 1.3× 533 1.4× 182 1.2× 111 0.8× 18 1.3k
Donna S. Dorow Australia 23 817 1.0× 180 0.4× 283 0.7× 113 0.7× 114 0.8× 33 1.3k
Marc Damelin United States 17 1.2k 1.5× 738 1.7× 237 0.6× 185 1.2× 175 1.3× 39 1.9k
Philipp F. Lange Canada 20 1.2k 1.5× 545 1.2× 101 0.3× 152 1.0× 219 1.6× 46 1.9k
Rastislav Tamaskovic Switzerland 12 913 1.1× 331 0.7× 311 0.8× 82 0.5× 405 2.9× 13 1.3k
Brett W. Stringer Australia 25 1.1k 1.3× 398 0.9× 110 0.3× 167 1.1× 241 1.7× 61 1.9k
Jan Olaf Stracke Switzerland 18 1.0k 1.2× 355 0.8× 728 1.9× 268 1.8× 64 0.5× 26 1.8k
S. Gräslund Sweden 21 1.1k 1.3× 125 0.3× 364 1.0× 129 0.9× 100 0.7× 43 1.5k

Countries citing papers authored by Christopher D. Thanos

Since Specialization
Citations

This map shows the geographic impact of Christopher D. Thanos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher D. Thanos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher D. Thanos more than expected).

Fields of papers citing papers by Christopher D. Thanos

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher D. Thanos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher D. Thanos. The network helps show where Christopher D. Thanos may publish in the future.

Co-authorship network of co-authors of Christopher D. Thanos

This figure shows the co-authorship network connecting the top 25 collaborators of Christopher D. Thanos. A scholar is included among the top collaborators of Christopher D. Thanos based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christopher D. Thanos. Christopher D. Thanos is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Wang, Lin, Luz M. Londono, Özge Saatci, et al.. (2021). Targeting Adenosine with Adenosine Deaminase 2 to Inhibit Growth of Solid Tumors. Cancer Research. 81(12). 3319–3332. 29 indexed citations
3.
Zhao, Chun‐Mei, Benjamin J. Thompson, Kelly Chen, et al.. (2019). The growth of a xenograft breast cancer tumor model with engineered hyaluronan-accumulating stroma is dependent on hyaluronan and independent of CD44. Oncotarget. 10(61). 6561–6576. 7 indexed citations
4.
5.
Serra, Sara, Cinzia Bologna, Luz M. Londono, et al.. (2017). Abstract 5583: Pegylated adenosine deaminase 2 (PEG-ADA2) abrogates the cytoprotective effects of adenosine against chronic lymphocytic leukemia cells. Cancer Research. 77(13_Supplement). 5583–5583. 3 indexed citations
6.
Shepard, H. Michael, Gail D. Lewis Phillips, Christopher D. Thanos, & Marc Feldmann. (2017). Developments in therapy with monoclonal antibodies and related proteins. Clinical Medicine. 17(3). 220–232. 164 indexed citations
7.
Gao, Feng, Lei Huang, Barbara Blouw, et al.. (2017). Abstract 50: HTI-1511, a novel anti-EGFR-ADC, overcomes mutation resistance and demonstrates significant activity against multiple tumor types in preclinical studies. Cancer Research. 77(13_Supplement). 50–50. 5 indexed citations
8.
DuFort, Christopher C., Kathleen E. DelGiorno, Markus A. Carlson, et al.. (2016). Interstitial Pressure in Pancreatic Ductal Adenocarcinoma Is Dominated by a Gel-Fluid Phase. Biophysical Journal. 110(9). 2106–2119. 128 indexed citations
9.
Wang, Lin, Sanna Rosengren, Lei Huang, et al.. (2016). Abstract 1472: Enzymatic depletion of adenosine by pegylated, engineered adenosine deaminase 2 (PEG-ADA2): A novel immunotherapeutic approach to treat solid tumors. Cancer Research. 76(14_Supplement). 1472–1472. 1 indexed citations
10.
Zhao, Chun‐Mei, Mathieu Marella, Lei Huang, et al.. (2016). Abstract A46: Hyaluronan-dependent growth of human triple negative breast cancer MDA-MB-468 in a mouse xenograft model with HA-high stroma. Cancer Research. 76(15_Supplement). A46–A46. 1 indexed citations
11.
Zimmerman, Erik S., Tyler H. Heibeck, Avinash Gill, et al.. (2014). Production of Site-Specific Antibody–Drug Conjugates Using Optimized Non-Natural Amino Acids in a Cell-Free Expression System. Bioconjugate Chemistry. 25(2). 351–361. 277 indexed citations
12.
Groff, Dan, Juan Zhang, Junhao Yang, et al.. (2014). Engineering toward a bacterial “endoplasmic reticulum” for the rapid expression of immunoglobulin proteins. mAbs. 6(3). 671–678. 51 indexed citations
13.
Thanos, Christopher D. & Dwaine F. Emerich. (2008). On the Use of Hydrogels in Cell Encapsulation and Tissue Engineering Systems. Recent Patents on Drug Delivery & Formulation. 2(1). 19–24. 9 indexed citations
14.
Thanos, Christopher D., Warren L. DeLano, & James A. Wells. (2006). Hot-spot mimicry of a cytokine receptor by a small molecule. Proceedings of the National Academy of Sciences. 103(42). 15422–15427. 106 indexed citations
15.
Emerich, Dwaine F. & Christopher D. Thanos. (2006). Intracompartmental Delivery of CNTF as Therapy for Huntingtons Disease and Retinitis Pigmentosa. Current Gene Therapy. 6(1). 147–159. 26 indexed citations
16.
Emerich, Dwaine F. & Christopher D. Thanos. (2005). Nanomedicine. Current Nanoscience. 1(3). 177–188. 7 indexed citations
17.
Kim, Chongwoo A., Martin L. Phillips, Cameron D. Mackereth, et al.. (2002). Oligomerization-dependent Association of the SAM Domains from Schizosaccharomyces pombe Byr2 and Ste4. Journal of Biological Chemistry. 277(42). 39585–39593. 35 indexed citations
18.
Thanos, Christopher D., Salem Faham, Kenneth E. Goodwill, et al.. (1999). Monomeric Structure of the Human EphB2 Sterile α Motif Domain. Journal of Biological Chemistry. 274(52). 37301–37306. 34 indexed citations
19.
Thanos, Christopher D. & James U. Bowie. (1999). p53 Family members p63 and p73 are SAM domain‐containing proteins. Protein Science. 8(8). 1708–1710. 127 indexed citations
20.
Thanos, Christopher D. & James U. Bowie. (1996). Developmentally expressed myosin heavy‐chain kinase possesses a diacylglycerol kinase domain. Protein Science. 5(4). 782–785. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Dorothea Reilly Breakdown of academic impact, for papers by Anna Maria Gasparri Breakdown of academic impact, for papers by M. Inoue Breakdown of academic impact, for papers by Donna S. Dorow Breakdown of academic impact, for papers by Marc Damelin Breakdown of academic impact, for papers by Philipp F. Lange Breakdown of academic impact, for papers by Rastislav Tamaskovic Breakdown of academic impact, for papers by Brett W. Stringer Breakdown of academic impact, for papers by Jan Olaf Stracke Breakdown of academic impact, for papers by S. Gräslund
Rankless by CCL
2026